跳至主要内容
临床试验/EUCTR2008-007024-26-DE
EUCTR2008-007024-26-DE进行中(未招募)不适用

A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 80876395) in a 21-day regimen as compared to a monophasic contraceptive containing ethinyestradiol and levonogestrel (0.33 mg/0.15 mg) in a 21-day regimen on hemostatic parameters in 30 women aged 18-35 years over 3 treatment cycles in each period - FC-Patch Metabolism Study

Bayer Healthcare AG0 个研究点开始时间: 2009年4月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - signed and dated informed consent
  • - healthy women requesting contrception
  • - age:18-35 years (inclusive), Smokers must be not older than 30 years at the time of informed consent
  • - normal cervical smear not requiring further follow-up
  • - history of regular cyclic menstrual periods
  • - willingness to use back-up contraception during the 2 washout cycles
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - pregnancy or lactation (less than 3 menstrual cycles since delivery, abortion or lactation before start of treatment)
  • - obesity (Body Mass Index >30.0 kg/m2)
  • - hypersensitivity to any ingredient of the study drug
  • - significant skin reaction to transdermal preparations or sensitivity to medical tape
  • - safety relevant laboratory values outside inclusion range before start of treatment
  • - diseases or conditions that can compromise the function of the body systems, may worsen under hormonal treatment or might interfere with the conduct of the study
  • - undiagnosed abnormal genital bleeding
  • - abuse of alcohol, drugs or medicines
  • - any medication that could result in excessive accumulation, impaired metabolism or altered excretion of the study drug or interfere with the contact of the study
  • - major surgery planned during study period

研究者

相似试验